Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Henkel AG and Co KGaA | 169 |
| 2 | Fujifilm Holdings Corp | 49 |
| 3 | BASF Schweiz AG | 29 |
| 4 | Memorial Sloan Kettering Cancer Center | 16 |
| 5 | Yale University | 13 |
| 6 | Takeda Pharmaceutical Co Ltd | 11 |
| 7 | BASF SE | 10 |
| 8 | Sumitomo Pharma Co Ltd | 10 |
| 9 | The University of Texas System | 10 |
| 10 | Institut National de la Santé et de la Recherche Médicale | 9 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 561 |
| 2 | A61P | Therapeutic activity (drug indications) | 420 |
| 3 | C07D | Heterocyclic compounds | 297 |
| 4 | A61Q | Cosmetics, personal care | 218 |
| 5 | C07K | Peptides | 103 |
| 6 | G01N | Investigating / analysing materials | 85 |
| 7 | C09B | 80 | |
| 8 | C12N | Microorganisms, enzymes | 77 |
| 9 | C07C | Acyclic and carbocyclic compounds | 54 |
| 10 | G03C | 32 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWhere research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Cytokine Signaling Pathways and Interactions | 1 |
| 2 | Immune Response and Inflammation | 1 |
| 3 | MicroRNA in disease regulation | 1 |
| 4 | Nanoparticle-Based Drug Delivery | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Anton Simeonov | National Center for Advancing Translational Sciences | 4 |
| 2 | James Inglese | National Center for Advancing Translational Sciences | 4 |
| 3 | Ajit Jadhav | National Center for Advancing Translational Sciences | 3 |
| 4 | Chenglong Li | The Ohio State University | 3 |
| 5 | Dingyin Tao | National Institutes of Health | 2 |
| 6 | Fei Chen | Wayne State University | 3 |
| 7 | Gerd Heusch | Essen University Hospital | 3 |
| 8 | Jamal Mohammadian | Tabriz University of Medical Sciences | 3 |
| 9 | Jiayuh Lin | The Ohio State University | 3 |
| 10 | Mehdi Sabzichi | University of Alberta | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Stattic: A Small-Molecule Inhibitor of STAT3 Activation and Dimerization | 2006 | 1112 | PI3K/AKT/mTOR signaling in cancer |
| Systemic inhibition of IL-6/Stat3 signalling protects against experimental osteoarthritis | 2016 | 374 | Osteoarthritis Treatment and Mechanisms |
| STAT3 Is Necessary for Proliferation and Survival in Colon Cancer–Initiating Cells | 2011 | 307 | Cancer Cells and Metastasis |
| Mitochondrial STAT3 Activation and Cardioprotection by Ischemic Postconditioning in Pigs With Regional Myocardial Ischemia/Reperfusion | 2011 | 301 | Organ Transplantation Techniques and Outcomes |
| STAT3 tyrosine phosphorylation is critical for interleukin 1 beta and interleukin-6 production in response to lipopolysaccharide and live bacteria | 2009 | 262 | Immune Response and Inflammation |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the chemical structure and molecular composition of Stattic?
What is the primary biological mechanism of action for Stattic?
Which organizations hold the most patent rights related to Stattic?
What therapeutic applications have been explored for Stattic in peer-reviewed literature?
How has patent and publication activity around Stattic changed in recent years?